GLP-1 Weight Loss Drug Prices in 2026: Wegovy, Ozempic, Mounjaro Compared

Prices checked on the manufacturers' own websites on September 24, 2026. Manufacturers can change or end these offers at any time, so confirm the price before you order.

The price of brand-name GLP-1 medication now depends mostly on how you pay: self-pay through a manufacturer pharmacy, a commercial insurance plan with a savings card, or Medicare. This guide lists the manufacturer self-pay prices we could verify, and what changed for compounded versions and Medicare.

Manufacturer self-pay prices

Medicine	Maker	Approved use (maker's page)	Self-pay price, checked September 24, 2026
Wegovy pill (semaglutide tablets)	Novo Nordisk	Weight management and cardiovascular risk reduction	$149/month (1.5 mg), $199/month (4 mg), $299/month (9 mg and 25 mg) at NovoCare Pharmacy
Wegovy pen (semaglutide injection)	Novo Nordisk	Weight management and cardiovascular risk reduction	$349/month (0.25 mg to 2.4 mg). New patients: $199/month for the first 2 monthly fills of 0.25 mg or 0.5 mg, offer through December 31, 2026. Wegovy HD 7.2 mg: $399/month
Ozempic pen (semaglutide injection)	Novo Nordisk	Type 2 diabetes	$349/month (0.25 mg, 0.5 mg, 1 mg), $499/month (2 mg). New patients: $199/month for the first 2 fills of 0.25 mg or 0.5 mg, through December 31, 2026
Zepbound (tirzepatide) KwikPen or single-dose vial	Eli Lilly	Weight management	$299/month (2.5 mg), $399/month (5 mg), $449/month (7.5 mg to 15 mg) if you refill within 45 days. Otherwise $499 (7.5 mg) or $699 (10 mg to 15 mg)
Mounjaro (tirzepatide)	Eli Lilly	Type 2 diabetes	Self-pay starting at $499/month through LillyDirect. Lilly lists the list price (wholesale acquisition cost) as $1,112.16 per fill

Wegovy and Zepbound are the brands labeled for weight management. Ozempic and Mounjaro are labeled for type 2 diabetes, which matters for insurance coverage and for the Medicare program below.

Compounded semaglutide and tirzepatide after the shortages

Compounding pharmacies were able to make copies of these drugs while they were on the FDA drug shortage list. That period is over:

Drug	FDA declared shortage resolved	503A pharmacy grace period ended	503B outsourcing facility grace period ended
Tirzepatide	December 19, 2024	February 18, 2025	March 19, 2025
Semaglutide	February 21, 2025	April 22, 2025	May 22, 2025

The FDA says compounded drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug, and it has published warnings about fraudulent compounded products, counterfeit Ozempic, and dosing errors with compounded semaglutide. If a seller offers "compounded semaglutide" today, ask what medical need it meets that the approved product does not.

Medicare: the GLP-1 Bridge

From July 1, 2026 through December 31, 2027, Medicare runs a temporary demonstration called the Medicare GLP-1 Bridge:

• Cost: a $50 monthly copayment for a one-month supply. The Part D deductible does not apply, the copayment does not count toward your Part D out-of-pocket costs, and Extra Help does not reduce it.
• Covered drugs, for weight management only: Foundayo (tablet), Wegovy (injection or tablet), and Zepbound KwikPen. Zepbound vials and single-dose pens are excluded.
• Who qualifies: adults 18 or older with Part D coverage and a BMI of 35 or more; or a BMI of 30 to 34.9 with diastolic heart failure, uncontrolled hypertension, or chronic kidney disease stage 3a or higher; or a BMI of 27 to 29.9 with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease.
• Who does not: people whose Part D plan already covers a GLP-1 for them, and people with type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease, per Medicare.gov.

Commercial insurance and savings cards

Novo Nordisk's savings offer lets commercially insured patients pay as little as $25 for Wegovy, with savings capped at $100 per month, for pickup at a local pharmacy. Government plan beneficiaries are excluded. The cap means the card does little if your plan does not cover the drug. Lilly states that people with Medicaid, Medicare, Medigap, DoD, VA, or TRICARE are not eligible for the Mounjaro Savings Card.

How to choose a way to pay

1. On Medicare Part D? Check the GLP-1 Bridge criteria above first. If you qualify, $50 per month is lower than any self-pay price in the table.
2. Commercially insured? Ask your plan whether it covers the drug for your diagnosis. If it does, the manufacturer savings card applies. If it does not, the $100 monthly savings cap means self-pay is usually the comparison to make.
3. Paying cash? Compare the manufacturer prices in the table for the dose you will actually reach, not just the starting dose. Zepbound's lower price for higher doses depends on refilling within 45 days.
4. Considering a compounded product? Ask the prescriber what medical need it meets that an approved product does not, which is the FDA's standard. Buy only from a state-licensed pharmacy that fills your prescription.
5. Interested in research? Search ClinicalTrials.gov for recruiting obesity studies near you, and ask each study team what participation costs.

You can compare current GLP-1 prices by pharmacy on our GLP-1 price page.

Sources

• NovoCare Pharmacy, Wegovy self-pay prices and Wegovy price guide (PDF). Checked September 24, 2026.
• NovoCare Pharmacy, Ozempic self-pay prices and indications. Checked September 24, 2026.
• LillyDirect, Zepbound self-pay prices and Mounjaro self-pay prices. Checked September 24, 2026.
• Lilly, Mounjaro pricing information (list price from a January 1, 2026 source). Checked September 24, 2026.
• U.S. Food and Drug Administration, FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize and FDA's concerns with unapproved GLP-1 drugs used for weight loss. Checked September 24, 2026.
• Medicare.gov, Weight loss drugs, and CMS, Medicare GLP-1 Bridge. Checked September 24, 2026.